Psilocybin Therapy Reduces Inflammation in Parkinson's Patients

• A small nonrandomized trial showed psilocybin therapy reduced systemic inflammation and mitochondrial stress in Parkinson's patients.
• The trial focused on patients with Parkinson's disease and mood dysfunction.
• Psilocybin, a psychedelic compound, showed potential in reducing inflammation based on human data.
• The study is one of the first to signal the potential of psychedelics to combat inflammation in neurodegenerative diseases.
• The findings suggest a possible new avenue for treating inflammation in Parkinson's disease.